XML 62 R31.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2

Note 12 - Segment Information (Tables)

9 Months Ended

Dec. 31, 2019

Notes Tables

Schedule of Segment Reporting Information, by Segment [Table Text Block]

		Three Months Ended December 31, 2019
		Sterilization and Disinfection Control				Instruments				Biopharmaceutical Development				Cold Chain Monitoring				Cold Chain Packaging				Total
Revenues (1)		$	11,619			$	10,014			$	5,637			$	4,156			$	229			$	31,655
Gross profit (loss)		$	8,098			$	6,520			$	(1,294	)		$	1,371			$	(18	)		$	14,677
Reconciling items (2)																							(19,880	)
Loss before income taxes																						$	(5,203	)

		Three Months Ended December 31, 2018
		Sterilization and Disinfection Control				Instruments				Biopharmaceutical Development				Cold Chain Monitoring				Cold Chain Packaging				Total
Revenues (1)		$	11,545			$	9,341			$	--			$	3,744			$	2,052			$	26,682
Gross profit		$	7,876			$	5,922			$	--			$	1,575			$	261			$	15,634
Reconciling items (2)																							(14,686	)
Earnings before income taxes																						$	948

		Nine Months Ended December 31, 2019
		Sterilization and Disinfection Control				Instruments				Biopharmaceutical Development				Cold Chain Monitoring				Cold Chain Packaging				Total
Revenues (1)		$	35,823			$	28,518			$	5,637			$	11,059			$	2,442			$	83,479
Gross profit (loss)		$	25,323			$	18,128			$	(1,294	)		$	3,741			$	394			$	46,292
Reconciling items (2)																							(42,471	)
Earnings before income taxes																						$	3,821

		Nine Months Ended December 31, 2018
		Sterilization and Disinfection Control				Instruments				Biopharmaceutical Development				Cold Chain Monitoring				Cold Chain Packaging				Total
Revenues (1)		$	34,475			$	26,776			$	--			$	9,917			$	5,521			$	76,689
Gross profit		$	23,660			$	16,909			$	--			$	4,203			$	530			$	45,302
Reconciling items (2)																							(38,648	)
Earnings before income taxes																						$	6,654

Reconciliation of Assets from Segment to Consolidated [Table Text Block]

		December 31, 2019				March 31, 2019
Sterilization and Disinfection Control		$	76,493			$	74,230
Instruments			32,286				30,911
Biopharmaceutical Development			196,366				--
Cold Chain Monitoring			31,022				32,179
Cold Chain Packaging (a)			132				1,590
Corporate and administrative			87,168				17,857
Total		$	423,467			$	156,767

X

- Definition

Tabular disclosure of all significant reconciling items in the reconciliation of total assets from reportable segments to the entity's consolidated assets.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8906-108599

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8924-108599

+ Details

Name:	us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock
Namespace Prefix:	us-gaap_
Data Type:	nonnum:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 25
-URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8813-108599

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=108376223&loc=d3e13816-109267

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 21
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8721-108599

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8906-108599

+ Details

Name:	us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock
Namespace Prefix:	us-gaap_
Data Type:	nonnum:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- References

No definition available.

+ Details

Name:	us-gaap_TableTextBlock
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration